{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-021189","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.511446+00:00","generated_at":"2026-05-15T08:49:30.545435+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen reports FY2025 net loss $121.3M; cash $116.9M; ALTITUDE-AD topline due late 2026","bullets":["Net loss $121.3M for FY2025 ($102.3M in FY2024); R&D expenses rose to $104.9M.","Cash, equivalents and marketable securities $116.9M as of Dec 31, 2025; expected to fund operations into early 2027.","Phase 2 ALTITUDE-AD (sabirnetug) topline results expected late 2026; OLE dosing commenced Nov 2025.","$35.75M private placement closed March 2026 to advance Enhanced Brain Delivery (EBD) program; IND filing targeted mid-2027.","EBD program candidates showed up to 40-fold brain exposure in NHPs; low anemia risk; subcutaneous potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-021189","json":"https://secwatch.observer/filing/0001628280-26-021189.json","markdown":"https://secwatch.observer/filing/0001628280-26-021189.md","text":"https://secwatch.observer/filing/0001628280-26-021189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/0001628280-26-021189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:49:30.545435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56f04ae04452332a3d773ac25e26a6a1a7639e14","claim":"Acumen Pharmaceuticals, Inc. reported the year ended December 31, 2025 results: net income Net loss was $121.3 million.","evidence_excerpt":"Net loss was $121.3 million for the year ended Dec. 31, 2025, compared to $102.3 million for the year ended Dec. 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/0001628280-26-021189-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"Net loss was $121.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}